DavidOMalleyMD

Obstetrics & Gynecology • Hilliard, OH

Gynecologic Oncology

Physician

Join to view full profile

Dr. OMalley is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. OMalley's full profile

Already have an account?

Office
3651 Ridge Mill Dr
Hilliard, OH 43026
Phone+1 614-293-3873

Fax+1 614-293-3078

Education & Training

Yale-New Haven Medical CenterFellowship, Gynecologic Oncology, 2002 - 2004
Cleveland Clinic FoundationResidency, Obstetrics and Gynecology, 1998 - 2002
Wayne State University School of MedicineClass of 1998

Certifications & Licensure

OH State Medical License 2005 - 2026
CT State Medical License 2002 - 2006
American Board of Obstetrics and Gynecology Obstetrics & Gynecology
American Board of Obstetrics and Gynecology Gynecologic Oncology

Clinical Trials

Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer Start of enrollment: 2010 Oct 01
Active, not recruiting
Phase 1
Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma Start of enrollment: 2007 Aug 01
Completed
Phase 2
Biomarkers for Gynecologic Cancer Start of enrollment: 2014 Jun 01
Unknown status
Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers Start of enrollment: 2019 Feb 01
Active, not recruiting
Phase 1
Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer Start of enrollment: 2019 Feb 27
Active, not recruiting
Phase 1, Phase 2
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations Start of enrollment: 2021 Jan 11
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

4 citations
Safety and feasibility of same-day discharge following minimally invasive hysterectomy in the morbidly obese patient population.
Paulina J Haight, David A Barrington, Stephen M Graves, Rachael N Piver, Jae Baek
Gynecologic Oncology. 2023-03-01
Correction: Targeting TMEM205 mediated drug resistance in ovarian clear cell carcinoma using oncolytic virus.
Uksha Saini, Brentley Q Smith, Kalpana Deepa Priya Dorayappan, Ji Young Yoo, G Larry Maxwell
Journal of Ovarian Research. 2023-02-13
4 citations
Targeting TMEM205 mediated drug resistance in ovarian clear cell carcinoma using oncolytic virus.
Uksha Saini, Brentley Q Smith, Kalpana Deepa Priya Dorayappan, Ji Young Yoo, G Larry Maxwell
Journal of Ovarian Research. 2022-12-07